Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Article About Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%AcneFeatured ArticlesLatest NewsThe Latest
April 24, 2025

Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%

Acne Treatment Without the Dry-Out: Clascoterone Cream 1% Proves Gentle on the Skin Barrier Topical acne meds often come with an unfortunate side effect: dry, irritated skin that leaves patients…
Journal of Drugs in Dermatology JDD Article About The State of the Clinical Management Union: A Cross-Sectional Survey of Persons With Hidradenitis SuppurativaAcneFeatured ArticlesLatest NewsThe Latest
April 23, 2025

The State of the Clinical Management Union: A Cross-Sectional Survey of Persons With Hidradenitis Suppurativa

April Issue Must-Read! Hidradenitis suppurativa (HS) isn’t just painful—it’s deeply isolating. And new data reveals why: the majority of people living with HS don’t feel heard, treated, or informed. In a…
Journal of Drugs in Dermatology JDD Article About An Algorithm Integrating Acneceuticals into the Management of Acne VulgarisAcneFeatured ArticlesLatest NewsThe Latest
April 22, 2025

An Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris

Did you miss this #acneceuticals article from April’s issue? What if your acne routine could be smarter, more personalized—and actually stick? Say hello to the new acne algorithm that’s changing…

Leave a Reply